marker of osteoblast maturation. These data suggest that the skeletal damage is directly linked to the absence of the receptor, which in turn leads to osteoblasts dysfunction and earlier maturation.
Phenotypic characterization of
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Introduction
The metabotropic glutamate (mGlu) receptors belong to family C G-protein coupled receptors. mGlu receptors are a heterogeneous subfamily with different subtypes and are divided into three groups based on sequence homology and signal transduction pathways. Group I consists of the mGlu1 and mGlu5 receptors, coded by the Grm1 and the Grm5 genes, respectively. mGlu1 receptor is primarily coupled to Gq/G11 protein and its activation stimulates phospholipase C β (PLC β) with the ensuing formation of the intracellular second messengers, inositol-1,4,5-trisphosphate (Ins-1,4,5-P3) and diacylglycerol (DAG) (reviewed in [1] ). In turn, Ins-1,4,5-P3 production leads to the release of Ca 2+ from intracellular stores, whereas DAG activates protein kinase C. The mGlu1 receptor is present in a number of key central nervous system (CNS) structures including the hippocampus, cortex, thalamus and cerebellum [2] . The receptor plays an important role in neuronal cells by triggering various signaling pathways that modulate neuron excitability, synaptic plasticity, and mechanisms of feedback regulation of neurotransmitter release [1, 3] . mGlu1 receptor is also expressed in nonneuronal tissues, e.g. skin, pancreas, liver, heart, retina and bone [4] [5] [6] [7] [8] [9] . In the kidney, mGlu1 receptors are present particularly in glomerular podocytes, where they play an important role in podocyte signaling and glomerular intercellular communication [8, 10] .
The implication of the glutamate signaling pathways in bone mass regulation has been studied extensively during the past years. Accumulating evidence supports the expression in bone cells of all functional elements of glutamate signaling [11] [12] [13] [14] [15] , particularly in cells responsible for bone remodeling, such as osteoblasts and osteoclasts. In addition, osteoblasts have been found to be able to release and recycle glutamate using mechanisms identical to those of neuronal cells [16, 17] .
Finally, functional mGlu1 receptor has been detected in primary culture of rat femoral osteoblasts, as demonstrated by the fact that its activation leads to an elevation of intracellular Ca 2+ levels [4] .
We previously described a mouse carrying a spontaneous recessive mutation in the Grm1 gene (crv4) [18] . The crv4 germline mutation affects constitutively all tissues and gives rise to a complex phenotype, mainly characterized by ataxia and tremor due to impaired cerebellar activities, renal 4 dysfunction, and kyphoscoliosis particularly evident in female mice [8, 18, 19] .
As for the skeletal phenotype, it could be an indirect consequence of neuronal and renal changes, or it can be directly caused by Grm1 expression absence in bone cells.
Based on the evidence that mGlu receptors are expressed in bone, we hypothesized that absence of Grm1 expression from osteoblasts could lead to impaired glutamate signaling and consequently to pathological changes in bone remodelling. Therefore, the aim of the current study was to conduct a detailed analysis of the skeletal phenotype of the Grm1 crv4 mice. To determine the impact of mGlu1 receptors absence on the skeletal phenotype in vivo, we analysed body weights and lengths of affected and wild type animals, and carried out bone histomorphology and blood biochemical analyses. The direct effects of constitutive Grm1 from osteoblasts were determined in vitro, in osteoblasts isolated from mice lacking Grm1, and from wild-type control animals. The results suggest that absence of mGlu1 receptor from osteoblasts directly contributes to the skeletal abnormalities present in Grm1 crv4/crv4 mice.
Materials and methods

Animal model and ethics statement
The crv4 mutation is a spontaneous recessive mutation occurred in the BALB/c/Pas inbred strain that disrupts the Grm1 splicing and causes absence of the mGlu1 receptor protein [18] . Affected (Grm1 crv4/crv4 ) and control (Grm1
) mice are maintained on the same genetic background by intercrossing Grm1 crv4/+ mice at the animal facility of the IRCCS San Martino-IST (Genoa, Italy).
Mice are given free access to water. Normal chow food is placed on the floor to ensure that all mice are fed in equal measure. To obtain the genotype of the mouse progeny, DNA was extracted from ear clippings according to the manufacturer's protocol (KAPA Mouse Genotyping Kits, Kapa
Biosystems, Woburn, MA, USA) and amplified via polymerase chain reaction (PCR) using specific primers as previously described [20] . In this study a total of 52 
Mouse body weight and body length measurements
Body weights and lengths of 10 males and 10 females WT and Grm1 crv4/crv4 were measured at 24 weeks of age. Body length was determined by measuring nasal-to-anal distance using a caliper immediately after the mice were killed before organ collection.
X-ray analysis, imaging techniques and image processing
Hind limbs of 12 to 28 weeks old sex-and genotype-matched mice were analysed. Mouse hind limbs were X-rayed and bone length and density were measured using the Bruker In-Vivo FX PRO imaging system (Foley et al, application note, in preparation and [21] ). Briefly, the X-ray energy was calibrated to 12.85 -13.03 Kev, thus the X-ray quantum efficiency is maximal at energy levels between 10 and 15 Kev [22] . Imaging and image processing were performed via Carestream (Bruker) Molecular Imaging Software v5.0.2. The software interface enables estimation of bone mineral density in a certain region of interest (ROI) selected by the user from the X-ray image [22] . The Xray images were processed with the Carestream software, rotated and mirrored, so that the femoral axis was as horizontal as possible and the images had the same orientation (the condyle on the left hand side and the femoral head on the right hand side). A standard size ROI was selected in the most cylindrical region of the bone. Bone length and surface density were calculated with the same tool.
Femur length was measured by drawing a straight horizontal line from the most exterior point of the femoral head, to the most exterior point of the condylar extremity. The tibia was measured in a comparable manner. 
Bone histomorphometry
ALP and TRACP staining
The activity staining of alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRACP) was carried out separately on mouse femur frozen tissue sections using a commercially available kit (Takara Bio) in which chromogenic substrates for alkaline phosphatase, an enzyme marker of osteoblasts, and tartrate-resistant acid phosphatase, an enzyme marker of osteoclasts, are used.
Briefly, after fixation with 45% citrate buffer and 10% acetone, the enzyme substrates were added on separate slides and incubated at 37°C. 
Osteoblast cultures and treatments
Primary osteoblasts were isolated from 4 weeks old mice of the three genotypes (WT, Grm1 crv4/+ and Grm1 crv4/crv4 ), according to a well-established procedure [25] . Briefly, calvaria were removed, parietal bones were cut in two halves, and subjected to four sequential digestion steps (15 min each, at 37 °C)
in PBS with 0.05 % CollagenaseP (Roche) and 0.1 % Trypsin (Thermo Fisher Scientific, MA, USA).
Cells from the first digestion were discarded, cells from the 2nd to the 4th digestion were placed in alpha-MEM medium (Thermo Fisher Scientific) supplemented with 10 % FBS and 1 % streptomycin/penicillin, 50 μg/mL ascorbic acid and 3 mM glycerol 2-phosphate disodium salt hydrate (Sigma-Aldrich, Milan, Italy). After 24 h medium was changed, thereafter, medium was changed every other day. When cells reached confluence, they were trypsinised and seeded at a density of 10,000 cells/cm 2 to get second passage cells. Cells were monitored daily to assess morphology, and experiments performed after 10 days of cultures. [20] , at a final concentration of 10 μM in 0.01% DMSO or with vehicle (DMSO 0.01%)
only. Treatment was repeated on alternate days for a total of 10 days, when osteoblasts reached confluence. All experiments were performed in triplicate.
Real-time Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) assay
Total RNA was extracted using Trizol (Invitrogen) from osteoblasts kept in culture for 10 days, as described above. cDNA was prepared from 3µg RNA using the iScript Select cDNA Synthesis Kit and oligo(dt)20 primers (Bio-Rad, Segrate, Milan, Italy). Gene expression levels were quantified using gene-specific primers (Supplementary file). Real Time RT-PCR was run with iQ Sybr Green Supermix (Bio-Rad) on a MyIQ instrument (Bio-Rad) and data were analysed by the IQ5 Bio-Rad Software.
The relative expression levels of mRNA from Grm1 crv4/crv4 osteoblast cells were calculated using the ΔΔCt method [26] normalizing to Gapdh and relative to WT cells. Three replica per mouse, and three mice per genotype were analysed.
Analogously, the relative expression levels of mRNA from CPCCOEt treated osteoblast cells were obtained using the ΔΔCt method [26] normalizing to Gapdh and relative to DMSO treated cells.
Alizarin red staining and extraction methods
Alizarin red staining solution (1 mg/mL, pH 5.5, Sigma-Aldrich) was added to ethanol-fixed osteoblasts then cells were destained by 5% perchloric acid. Optical density of the supernatant was evaluated by spectrophotometry at 450 nm. To normalize, Yanus Green Whole-cell Stain was added for 10min followed by Elution buffer and absorbance was read at 615nm. All experiments were 10 carried out using 3 replicates per each treatment.
ALP activity
To evaluate ALP activity in cultured cells, the medium was removed, the wells rinsed once with PBS, and 0.2 ml p-nitrophenyl phosphate (pNPP) (Sigma-Aldrich) was added to the wells and incubated for 30 seconds at room temperature in the dark. The reaction was stopped by the addition of 3 N NaOH and the sample was analyzed at 405 nm by the GloMax-Multi Detection System (Promega, Madison, WI, USA). The amount of protein was determined using a Pierce BCA Protein Assay kit (Thermo-Fischer Scientific), and the absorbance was read at 560 nm with the GloMax-Multi Detection System. ALP activity was defined by dividing the values from the pNPP assay by the values from BCA total protein to represent normalized alkaline phosphatase activity per unit total protein.
Sirius Red staining
Osteoblast cells were fixed in 4 % paraformaldehyde, then Sirius red solution (Polysciences, inc, Warrington, PA, USA) was added and washed with tap water after 1 hour incubation. Cells were destained by NaOH 0.1M. Optical density of the supernatant was evaluated by spectrophotometry at 540 nm wavelength. To normalize, Yanus Green Whole-cell Stain (Fisher Scientific, Rodano Milan, Italy) was added for 10min followed by Elution buffer and absorbance was read at 595 nm. All experiments were carried out using 3 replicates per each mouse, and three mice per genotype.
Statistics
Analysis of variance (ANOVA) was used for continuous, normally-distributed variables; Tukey posthoc test was used to determine significance between multiple groups. Comparisons between two groups were carried out using an unpaired, two-tailed Student's t test. The Kruskal Wallis nonparametric test was used when the normality assumption was violated, in which case the Wilcoxon-Mann-Whitney test was used for pairwise comparisons. Between subjects t-test using Levine's test for equality of variances was used to assess differences in bone parameters. For all statistical analyses, a p-value less than 0.05 was considered to be statistically significant. 
Results
Grm1 crv4/crv4 mice exhibit impaired skeletal development in vivo compared to WT animals
The body weight of homozygous mutant mice was reduced with respect to that of WT mice of about 25%. Analogously, body length of Grm1 crv4/crv4 mice was about 10% shorter than that of WT mice.
Heterozygous Grm1 crv4/+ did not exhibit any differences in weight or length compared to that of WT animals ( Figure 1 A- weeks) showed a statistically significant decrease of femoral length both in female and in male Grm1 crv4/crv4 mice when compared to WT females and males ( Figure 1D ). Femur length of Grm1 crv4/crv4 female and male mice was shorter also with respect to heterozygous Grm1 crv4/+ female and male counterparts ( Figure 1D ). Tibial length of the homozygous mutant female and male mice was shorter than that of WT females and WT males, respectively, the difference being statistically significant only in female animals ( Figure 1D ). Femoral length and tibia length of heterozygous Bone mineral density of male Grm1 crv4/crv4 mice showed a statistically significant reduction when compared to WT and Grm1 crv4/+ mice ( Figure 1E ). Similarly, bone surface density of male Grm1 crv4/crv4 mice was significantly reduced with respect to that of WT and of Grm1 crv4/+ mice ( Figure   1E ). In the female animals no difference in bone mineral density and bone surface density could be detected when mice of pooled ages (12 -28 weeks) were analysed (Supplementary Figure 1C, 1D ).
When only animals of 24 weeks of age were considered, a statistically significant reduction in bone mineral density of female Grm1 crv4/crv4 with respect to WT mice and, accordingly, bone surface density in Grm1 crv4/crv4 with respect to WT mice was observed ( Figure 1E ). There was no statistically significant difference of either bone mineral density or surface density between heterozygous bone growth is still an on-going process in 24 weeks old WT mice, while in the 24 weeks old Grm1 crv4/crv4 mice the growth plate fused, ceasing the longitudinal bone growth. Overall, these data suggest that bone growth terminates earlier in the Grm1 crv4/crv4 than in the WT mice.
We wondered if this observation was associated to an imbalance in the number of osteoblasts/osteoclasts in the mutated bone tissues. By using enzymatic histochemistry we evaluated the presence of ALP-positive osteoblasts and TRACP-positive osteoclasts at bone epiphysis of WT and Grm1 crv4/crv4 mice. This double staining analysis did not reveal any difference in number and/or distribution of osteoblasts and osteoclasts in the mutated with respect to the WT tissues ( Figure 2B ). 13 Indeed, we performed double immunofluorescence analyses with antibodies specific for Runx2, as marker for osteoblasts, and the mGlu1 receptor in diaphysis ( Figure 3A-C) . As expected, Runx2 and mGluR1 double positive cells were clearly observable in the wild type tissues and absent in the mutated bone. To note, no difference in the number of osteoblasts (Runx2-positive cells) was observable between mutated and wild type tissues. We than analysed bone epiphysis of WT and mutated mice by double immunofluorescence using antibodies specific for the osteoclast marker, CD68, and for the mGlu1 receptor ( Figure 2D-G) . No difference in the number of osteoclasts (CD68-positive cells) was observable between mutated and wild type tissues. Of note, a few CD68-expressing osteoclasts also expressed mGlu1 receptors ( Figure 2E ).
We next carried out histomorphometry on toluidine blue-stained bone sections from 6-week-old wild type and Grm1 crv4/crv4 mice ( Figure 4A-B) . Here, we observed a moderate enrichment of the bone surface and of the trabecular number in the mutated relative to wild type animals.
We than investigated whether the bone formation could be different in the affected animals ( Figure   4C -D). By 20 weeks, MAR and BFR/BS were both significantly decreased (MAR: 34%; BFR/BS: 40%) in the femora of Grm1 crv4/crv4 compared to those from WT mice. figure 3) .
No evident serum biochemical alterations are present in the Grm1
Absence of mGlu1 receptor impairs osteoblast differentiation and mineralization in vitro
To test whether decreased bone formation was directly caused by absence of mGlu1 receptor in osteoblasts, we studied the effects of genetic inactivation of mGlu1 receptor on osteoblast As collagen is the major matrix component released from osteoblasts, we examined the possibility that the quantity of collagen released from Grm1 crv4/crv4 mice osteoblasts was reduced with respect to the quantity released from WT cells. To this purpose, we first evaluated the SiriusRed staining, which specifically stains for collagen regardless of its different isoforms, and did not detect statistically significant differences between WT and mutated cells ( Figure 5D ). We then examined the expression of type I collagen, the prevalent component of bone matrix in homeostatic conditions, and found an abnormal distribution of type I collagen in the matrix of the mutant as compared to the WT cells ( Figure 5E ). Specifically, osteoblasts derived from Grm1 crv4/crv4 mice showed a more scattered collagen distribution and less nodular appearance than those obtained from WT animals. CPCCOEt when compared to control cells (p<0.05) ( Figure 5H ), confirming that mGlu1 receptor activity is required for osteoblast homeostasis. Finally, we performed real-time qRT-PCR to evaluate whether any differences were present in the expression of collagen type 1, collagen type 3, and the osteoblast markers Runx2, Osterix (Sp7) and Osteocalcin (Bglap) at mRNA level ( Figure 6 ). No differences were evident except for osteocalcin, which was significantly more expressed in osteoblasts of Grm1 crv4/crv4 with respect to WT cells.
Discussion
While it is well known that glutamate signaling pathways play a major role in the regulation of bone formation and dynamics, most studies have focused on ionotropic glutamate receptors. In contrast, the relevance of metabotropic glutamate signaling on bone mass regulation has not been investigated.
In humans, GRM1 inactivating mutations lead to a form of recessive ataxia known as SCAR13 and, thus far, all patients reported to be affected by SCAR13 exhibit below the normal range head circumference and weight, both at birth and later during infancy; indeed, they show short stature in adult age (143-154 cm) [27, 28] . Consistent with these findings, previously we have shown that mice in which Grm1 is mutated exhibit cerebellar ataxia, impaired gait, kyphoskolyosis and reduced body weight and length compared to WT animals [18] . While the skeletal phenotype could be the direct consequence of both neuronal and renal abnormalities seen in these mice, as the bone is equipped 16 with all functional elements of the glutamate signaling, we hypothesized that the GRM1 ablation could account for the skeletal phenotype both seen in SCAR13 patients and in Grm1 crv4/crv4 mice. To test this hypothesis directly, we carried out a detailed characterisation of the skeletal phenotype of the Grm1 crv4/crv4 mice, specifically directed at testing the contribution that mGlu1 receptor makes to osteoblast function.
In adult female and male Grm1 crv4/crv4 mice we mainly observed reduced femoral length, reduced bone mineral density and bone surface density when compared to age-matched WT animals. Differences in bone mineral and bone surface density were predominantly visible in older mice, suggesting that the observed reduction in bone mass is age-related. Accordingly, Grm1 crv4/crv4 mice exhibited reduced mineralization and bone apposition rates compared to WT mice at 24 weeks of age.
Unlike in humans, in rodents the longitudinal bone growth continues even after they reach sexual maturity [29] . When analysing the morphology of the 12 and 24 weeks bone in Grm1 crv4/crv4 and WT mice, it was discovered that the growth plate, still very much active in both genotypes at 12 weeks of age, at 24 weeks of age in Grm1 crv4/crv4 mice the transformation of the growth plate into epiphyseal line was already completed while longitudinal bone growth in WT mice has still not ceased.
Histomorphometry of the tibia from Grm1 crv4/crv4 mice indicated a slight increase of bone surface and trabecular number compared to WT mice at 6 weeks of age, features suggestive of enhanced bone maturation at this age. We performed toluidine blue staining to distinguish in epiphyseal plate metachromatic cartilage (blue dark border) from trabecular bone tissue; these data suggest that the absence of the mGlu1 receptor causes a premature cessation of the epiphyseal plate in the Grm1 crv4/crv4 mice, with subsequent reduction of bone length in the Grm1 crv4/crv4 compared to the WT mice.
It is well acknowledged that renal damage interferes with bone apposition, resulting in reduction of bone density and diameter. In particular, blood and urine sampled from patients with chronic renal failure present elevated levels of serum phosphorus and decreased levels of Ca 2+ and vitamin D, feature markers that indicate the onset of bone dystrophy [30] . Of note, the Grm1 crv4/crv4 mice exhibit an impaired renal function [8] , which is also necessary for the preservation of bone integrity. Noteworthy, osteoblasts obtained from mutated mice have a reduced ability to form mineralized matrix, when compared to WT cells. In addition, mineralized matrix production by WT osteoblasts was impaired when these cells were treated with a mGlu1 receptor specific inhibitor.
Differences between WT and Grm1 crv4/crv4 mice in collagen release from osteoblasts cultures were not evident. At RNA level, collagen 1 and 3, the most expressed collagens in the bone matrix, do not seem to be more expressed in osteoblasts culture from WT than in Grm1 crv4/crv4 mice cells, but immunostaining showed differences in collagen type I distribution, and a reduced production of collagen I was detected after mGlu1 receptor blockade by CPCCOEt. This first confirms that mGlu1 receptor activity is required for osteoblast functioning, and suggests that congenital absence of the 18 receptor might induce compensatory mechanisms. Actually, osteoblast cells obtained from Grm1 crv4/crv4 mice express higher levels of osteocalcin than those obtained from WT animals, suggesting a different maturation pattern. Indeed, osteocalcin is a marker of late osteoblast differentiation [31] , which supports a more rapid maturation of mutated cells, and is in line with the observed premature cessation of the epiphyseal plate in the Grm1 crv4/crv4 mice in vivo.
Overall, our studies show that the impaired bone formation in the Grm1 crv4/crv4 mice is most likely explained by osteoblast malfunction. This finding is in agreement with the findings reported previously on the ability of osteoblasts to release and recycle glutamate [16, 17] .
In the central nervous system, the mGlu1 receptor is primarily coupled to Gq/G11 protein and its activation leads to IP3 formation and releases of Ca 2+ from intracellular stores (reviewed in [1] ). In primary culture of rat femoral osteoblasts, it has been suggested that activation mGlu1 receptors is linked to an elevation of intracellular Ca 2+ levels [4] . Molecular mechanisms regulating intracellular calcium homeostasis are fundamental for adequate osteoblast function and differentiation. In the nervous system and in other non-neural tissues Group-I mGlu receptors also signal via activation of the MAPK and PI3K pathways and ERK1/ERK2 [1] , all of which are known important factors contributing to osteoblast function, as evidenced by fact that their genetic inactivation inhibits osteoblast differentiation [32] . Thus, activation of mGlu1 receptor in bone could also lead to activation of these signaling pathways and therefore play a crucial role in bone biology. Impairment of this process could contribute to the observed skeletal phenotype in patients affected by GRM1 inactivating mutations and in Grm1 crv4/crv4 mice.
Finally, mGlu receptors are reported to have a role also in the control of neuroendocrine function [33] , including modulatory effects on pituitary function [34] .
Thus, inactivation of mGlu1 receptor may have many different effects in different tissues and organs, including bone, nervous system, kidney, which may contribute together to the complex phenotype observed in the Grm1 crv4 mice. 
Conclusions
In summary, this work reveals a novel role for metabotropic glutamatergic signaling in bone. We show here that in the absence of mGlu1 receptors bone growth is altered, and that osteoblasts mGlu1 receptors are necessary for skeletal development, longitudinal bone growth and production of normal bone matrix. Further experimental work will be necessary to clarify the mechanisms linking mGlu1
receptors and bone physiology and to clarify to what extent mGlu1 receptors may contribute to bone formation and maintenance. 
